SCF API DEVELOPMENT PIPELINE FOR INDEVIRATE
Phase 8 Deliverable: Translational Blueprinting (Biomarkers, Clinical Endpoints, IND Strategy)
1. Phase 8 Objective
To convert the fully engineered Indevirate system into a regulatory-ready translational framework, including:
- Biomarker panels aligned to SCF multi-omics
- Clinical endpoints for efficacy and safety
- IND-enabling strategy (CMC, preclinical, clinical design)
- FDA pathway alignment for a new chemical entity (NCE)
This phase bridges SCF mechanistic architecture → clinical execution in accordance with FDA drug development processes.
2. Translational Positioning
2.1 Product Classification
Attribute | Classification |
Drug Type | Small-molecule antiviral (NCE) |
Delivery System | Lipid–Polymer Nanoparticle (LPNP) |
Indication | HIV-1 infection (reservoir suppression focus) |
Mechanistic Class | Dual-node viral genome arrest + immune stabilization |
3. Step 8.1 — SCF Biomarker Panel Design
3.1 Multi-Omics Biomarker Matrix
Omics Layer | Biomarker | Function | Clinical Relevance |
Genomic | HIV proviral DNA | Viral reservoir size | Primary efficacy marker |
Transcriptomic | Viral RNA (plasma) | Active replication | Viral suppression |
Proteomic | HIV p24 antigen | Viral protein expression | Treatment response |
Immunologic | CD4+/CD8+ ratio | Immune restoration | Clinical progression |
Cytokine panel | IL-6, TNF-α | Inflammatory state | Safety & immune modulation |
Metabolomic | ATP/ADP ratio | Cellular energy status | Toxicity/efficacy balance |
Redox markers | ROS, glutathione | Oxidative stress | Resistance modeling |
3.2 SCF Biomarker Clusters
Cluster | Purpose |
Viral Suppression Cluster | RNA, DNA, p24 |
Immune Restoration Cluster | CD4/CD8, cytokines |
Metabolic Stability Cluster | ATP, redox markers |
4. Step 8.2 — Clinical Endpoint Design
4.2 Primary Endpoints
Endpoint | Definition |
Viral Load Reduction | ≥2 log reduction in HIV RNA |
Reservoir Reduction | Decrease in proviral DNA |
Time to Viral Suppression | <12 weeks |
4.3 Secondary Endpoints
Endpoint | Definition |
CD4+ T-cell recovery | Increase from baseline |
Inflammatory marker reduction | IL-6, TNF-α decrease |
Safety/tolerability | Adverse event profile |
PK parameters | Cmax, AUC, t½ |
4.4 Exploratory Endpoints
Endpoint | Purpose |
Viral rebound delay | Resistance evaluation |
Immune memory restoration | Long-term benefit |
Mitochondrial function | Metabolic recovery |
5. Step 8.3 — Preclinical Development Plan
5.1 Required Studies (IND-Enabling)
Study Type | Objective |
In vitro antiviral assays | Confirm viral inhibition |
Resistance selection studies | Evaluate mutation barrier |
PK/PD studies (animal) | Dose-response modeling |
Toxicology (GLP) | Safety profile |
Biodistribution | Target tissue validation |
5.2 Animal Models
- Humanized mouse models (HIV infection)
- Non-human primates (PK and safety validation)
6. Step 8.4 — IND Strategy
6.1 IND Submission Components
Section | Content |
Preclinical Data | Efficacy, PK/PD, toxicology |
CMC | Manufacturing, formulation (LPNP) |
Clinical Protocol | Phase I trial design |
Investigator Brochure | Safety + mechanism summary |
6.2 Regulatory Pathway
Pathway | Justification |
505(b)(1) NDA | New chemical entity |
Fast Track | HIV = serious condition |
Breakthrough Therapy (potential) | If early efficacy strong |
7. Step 8.5 — Clinical Trial Design
7.1 Phase I
Parameter | Design |
Population | Healthy volunteers / HIV patients |
Objective | Safety, PK |
Size | 20–80 subjects |
7.2 Phase II
Parameter | Design |
Population | HIV-positive patients |
Objective | Efficacy + dose optimization |
Size | 100–300 patients |
7.3 Phase III
Parameter | Design |
Population | Large HIV cohort |
Objective | Confirm efficacy vs standard care |
Size | 1,000–3,000 patients |
8. Step 8.6 — SCF Translational Mapping
8.1 SCF PCR → Clinical Translation
SCF Mode | Clinical Equivalent |
Preventative | Viral suppression maintenance |
Curative | Active viral reduction |
Restorative | Immune recovery endpoints |
9. Step 8.7 — Companion Diagnostic Strategy
9.1 Diagnostic Tools
- qPCR (viral RNA/DNA quantification)
- Flow cytometry (CD4/CD8 profiling)
- ELISA (p24 antigen)
- Metabolomic assays (ATP/redox)
10. Step 8.8 — Manufacturing & CMC Considerations
10.1 Key Requirements
Component | Requirement |
API synthesis | Scalable cordycepin analog production |
Nanoparticle formulation | Reproducible LPNP system |
Stability testing | Shelf-life validation |
Quality control | Purity, potency, consistency |
11. Phase 8 Outcome
11.1 Translational Readiness Achieved
- Defined biomarker panels
- Established clinical endpoints
- Completed IND strategy
- Designed clinical development pathway
12. Final Conclusion — Indevirate Development Status
Indevirate is now:
- Fully engineered (Phases 1–6)
- Synergy-validated (Phase 3)
- Safety and resistance-modeled (Phase 7)
- Translationally ready (Phase 8)
Final Status:
IND-ENABLING STAGE — READY FOR PRECLINICAL EXECUTION
Master Registry Index
SCF-ETHBIO-WF-0001 — Ethnobioprospecting Workflow
SCF-SEF-MD-0001 — Synergistic Evaluation Framework
SCF-PATH-0001 — SCF Pathophysiology Protocol
SCF-FDA-0001 — FDA Drug Approval Framework
SCF-REG-HIV-INDEVIRATE-P8-0001 — Indevirate Phase 8 Translational Blueprint Deliverable